Evidence map›Paper›PMID 39103919›Full record

ReviewImmunity & ageing : I & A2024

Harnessing immunomodulation to combat sarcopenia: current insights and possible approaches.

Ning Zhang, Liting Zhai, Ronald Man Yeung Wong, Can Cui, Sheung-Wai Law, Simon Kwoon-Ho Chow, Stuart B Goodman, Wing-Hoi Cheung

Abstract readReview
In one paragraph

Review in Immunity & ageing : I & A, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ning ZhangDepartment of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, China. ningzhang@cuhk.edu.hk.
Liting ZhaiSchool of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Ronald Man Yeung WongDepartment of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, China.
Can CuiDepartment of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, China.
Sheung-Wai LawDepartment of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, China.
Simon Kwoon-Ho ChowDepartment of Orthopaedic Surgery, Stanford University, Stanford, CA, USA.
Stuart B GoodmanDepartment of Orthopaedic Surgery, Stanford University, Stanford, CA, USA.
Wing-Hoi CheungDepartment of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, China. louischeung@cuhk.edu.hk.

Funding

Collaborative Research Grant C4032-21GFCUHK Direct Grant for Research 4054760General Research Fund 14114822
6 · The paper itself

Abstract

Sarcopenia is a complex age-associated syndrome of progressive loss of muscle mass and strength. Although this condition is influenced by many factors, age-related changes in immune function including immune cell dynamics, and chronic inflammation contribute to its progression. The complex interplay between the immune system, gut-muscle axis, and autophagy further underscores their important roles in sarcopenia pathogenesis. Immunomodulation has emerged as a promising strategy to counteract sarcopenia. Traditional management approaches to treat sarcopenia including physical exercise and nutritional supplementation, and the emerging technologies of biophysical stimulation demonstrated the importance of immunomodulation and regulation of macrophages and T cells and reduction of chronic inflammation. Treatments to alleviate low-grade inflammation in older adults by modulating gut microbial composition and diversity further combat sarcopenia. Furthermore, some pharmacological interventions, nano-medicine, and cell therapies targeting muscle, gut microbiota, or autophagy present additional avenues for immunomodulation in sarcopenia. This narrative review explores the immunological underpinnings of sarcopenia, elucidating the relationship between the immune system and muscle during ageing. Additionally, the review discusses new areas such as the gut-muscle axis and autophagy, which bridge immune system function and muscle health. Insights into current and potential approaches for sarcopenia management through modulation of the immune system are provided, along with suggestions for future research directions and therapeutic strategies. We aim to guide further investigation into clinical immunological biomarkers and identify indicators for sarcopenia diagnosis and potential treatment targets to combat this condition. We also aim to draw attention to the importance of considering immunomodulation in the clinical management of sarcopenia.

Indexed as

AutophagyGut microbiotaImmune systemImmunomodulatory approachesSarcopenia

Identifiers

PMID39103919
PMCPMC11299351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.